Phase 1, first-in-human, randomized, placebo-controlled, dose-escalating study to evaluate OVX033, a nucleocapsid-based SARS-CoV-2 candidate vaccine. (academic.oup.com)

Authors: Launay O … Nicolas F Journal: Journal of Infectious Diseases Published: 2026-08-12 DOI: https://doi.org/10.1093/infdis/jiag409